XML 17 R5.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Operations - USD ($)
shares in Millions, $ in Millions
 6 Months Ended 12 Months Ended
Dec. 31, 2020
Dec. 31, 2021
Jun. 30, 2020
Jun. 30, 2019
Total revenue $ 299.8 $ 690.6 $ 638.6 $ 851.1
Costs and expenses:        
Research and development expense 35.8 81.9 77.2 85.9
Selling, general, and administrative expense 260.4 537.8 507.3 556.6
Legal charges pending settlement 0.0 62.0 0.0 0.0
Goodwill and long-lived asset impairment charges 0.0 1.8 99.7 0.0
Total costs and expenses 387.6 881.1 870.3 843.5
Operating income (loss) (87.8) (190.5) (231.7) 7.6
Other income (expense):        
Interest income 0.7 0.7 3.0 3.2
Interest expense (5.8) (6.6) (10.8) (12.0)
Other (1.2) 139.3 16.2 1.2
Total other income (expense) (6.3) 133.4 8.4 (7.6)
Income (loss) before income tax (94.1) (57.1) (223.3) 0.0
Income tax benefit (41.0) (29.9) (23.7) (4.4)
Net income (loss) (53.1) (27.2) (199.6) 4.4
Net loss attributable to non-controlling interest 0.0 0.0 (0.1) (0.2)
Net income (loss) attributable to Myriad Genetics, Inc. stockholders $ (53.1) $ (27.2) $ (199.5) $ 4.6
Earnings (loss) per share:        
Basic (in dollars per share) $ (0.71) $ (0.35) $ (2.69) $ 0.06
Diluted (in dollars per share) $ (0.71) $ (0.35) $ (2.69) $ 0.06
Weighted average shares outstanding:        
Basic (weighted average shares) 75.0 78.0 74.3 73.5
Diluted (weighted average shares) 75.0 78.0 74.3 76.0
Molecular diagnostic revenues        
Total revenue $ 279.6 $ 666.4 $ 586.9 $ 789.4
Costs and expenses:        
Costs and expenses 82.6 185.7 157.5 168.2
Pharmaceutical and clinical services        
Total revenue 20.2 24.2 51.7 61.7
Costs and expenses:        
Costs and expenses $ 8.8 $ 11.9 $ 28.6 $ 32.8